Eli Lilly & Co (LLY) Institutional Investor Snapshot (4637 Funds, Q2 2026)

LLY ranks #13 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

LLY is a top-conviction position for Lilly Endowment Inc — at 100.0% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

SG Americas Securities, LLC has added to its LLY position for two straight quarters, increasing it by $2.1B to reach $2.4B today.

T. Rowe Price has trimmed its LLY position for two straight quarters, cutting it by $1.1B while still holding $60.6M.

LLY is down 3.6% today, but institutions show net buying of $641.6B this quarter — a divergence between today's price move and the underlying institutional flow.

LLY posted net income of $26.7B over the trailing twelve months, and currently trades at a P/E of 40.0.

• Profitable — net income of $26.7B over the trailing twelve months
• Revenue grew 49.6% year over year
• Net income improved year over year, from $13.8B to $26.7B
• Generated $16.8B in positive operating cash flow
• Current ratio of 1.58x — enough short-term assets to cover short-term liabilities
• Liabilities run 4.24x equity — a highly leveraged balance sheet worth noting